Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection
Middle East respiratory syndrome (MERS) continues to raise worldwide concerns due to its pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the need to develop safe and effective vaccines against MERS. We have previously demonstrated that a receptor-binding domain (RBD)...
Saved in:
Main Authors: | Yufei Wang (Author), Wanbo Tai (Author), Jie Yang (Author), Guangyu Zhao (Author), Shihui Sun (Author), Chien-Te K. Tseng (Author), Shibo Jiang (Author), Yusen Zhou (Author), Lanying Du (Author), Jimin Gao (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2017-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prospects for a MERS-CoV spike vaccine
by: Yusen Zhou, et al.
Published: (2018) -
MERS-CoV
by: Du, Lanying
Published: (2019) -
MERS-CoV diagnosis: An update
by: Sameera Al Johani, et al.
Published: (2016) -
Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen
by: Rahul Ahuja, et al.
Published: (2024) -
Co-infection of MERS-CoV and SARS-CoV-2 in the same host: A silent threat
by: Buket Baddal, et al.
Published: (2020)